

Cantuzumab ravtansine (ADC)

Summary

Target

Catalog No. DHD14298

Alternative Names C242-DM4

Clone ID Cantuzumab ravtansine

Species reactivity Human

Form Liquid

Concentration 1 mg/ml

Purity >90% as determined by SEC.

Clonality Monoclonal

Applications Research Grade Biosimilar

PEMT, CA 15-3, H23AG, Peanut-reactive urinary mucin, PEM, EMA, Cancer antigen 15-3, MUC-1, Episialin, MUC1-CT, MUC1-beta, Tumor-associated

mucin, CD227, Polymorphic epithelial mucin, KL-6, MUC1-alpha, MUC1,

PUM, Krebs von den Lungen-6, MUC1-NT, Tumor-associated epithelial membrane antigen, Mucin-1, Breast carcinoma-associated antigen DF3,

Carcinoma-associated mucin

Purification Purified by Ion Exchange Chromatography.

Endotoxin level Please contact with the lab for this information.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stability and Storage Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -

80°C long term.

Note For research use only. Not suitable for clinical or therapeutic use.





Description

Cantuzumab ravtansine is an ADC consisting of a CanAg-directed antibody and DM4 that has extensive antitumor efficacy in a series of CanAg-positive human tumor xenografts.

Data Image